PubMed · 2002 · 26 citations · 26 references
MedicineGeneticsOncologyCarcinogenesisMolecular OncologyOncogenesBcl-2 Family ProteinsCancer ProgressionOncogene ActivationRas Family OncogenesTumor Suppressor GenesApoptotic ResponseSusceptibility Gene FunctionTerminal Deoxynucleotidyl Transferase Dutp Nick End LabelingTransgenic Mouse Cancer ModelsTransgenic Mouse ModelsTumor Cell ProliferationTumor Proliferation AssessmentTumor Resistance
The efficiency of tumor induction by oncogenes is influenced by modifier genes that determine individual susceptibility. We have used a transgenic mouse model to examine the role of a candidate susceptibility gene, bcl-2, for development of Raf oncogene-induced lung adenomas. Loss of bcl-2 greatly retarded tumor development without affecting tumor phenotype. Tumor tissues from bcl-2 positive and negative mice were compared for the fraction of S phase cells by staining for proliferating cell nuclear antigen and for the fraction of apoptotic cells by terminal deoxynucleotidyl transferase-mediated nick end labeling assay. The data indicate that the increased tumor latency in the absence of bcl-2 results primarily from an increased apoptotic rate but also involves a decrease in tumor cell proliferation. Both effects can be rescued by breeding with H2K-bcl-2 transgenic mice demonstrating that loss of bcl-2 was the major genetic factor determining tumor resistance. These findings suggest that bcl-2 is a major susceptibility gene for development of lung cancer in mice and perhaps in humans.
26
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Leisa Johnson, Kim L. Mercer, Doron C. Greenbaum et al. · Nature · 2001 · 1.2K citations
Bcl-2 Targets the Protein Kinase Raf-1 to Mitochondria
Hong‐Gang Wang, Ulf R. Rapp, John C. Reed · Cell · 1996 · 779 citations · Full text
Galen H. Fisher, Shari L. Wellen, David S. Klimstra et al. · Genes & Development · 2001 · 588 citations · Full text